← Issue №20/ week of Nov 15, 2026/IBD

Comparative effectiveness of infliximab and tofacitinib in advanced therapy-naive and -exposed patients with ulcerative colitis: a multicenter real-world study.

From GI Signals issue №20: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD retrospective · n=266 · Nov 10, 2026 · Inflamm Bowel Dis · IF 4.5

Comparative effectiveness of infliximab and tofacitinib in advanced therapy-naive and -exposed patients with ulcerative colitis: a multicenter real-world study.

New evidenceulcerative colitisJAK inhibitorsbiologicstherapeutic drug monitoring
Clinical takeawayTreat as exploratory: tofacitinib's week-52 advantage was nominal in advanced-therapy-exposed patients (P = .034) and not significant in naive patients (OR 2.32, 95% CI 0.84-6.44); 3-year persistence did not differ significantly.
What it foundAt week 52, corticosteroid-free clinical remission was higher with tofacitinib (TOF) vs infliximab (IFX) in advanced therapy (AT)-exposed patients (38.8% vs 19.0%; OR 2.71, 95% CI 1.08-6.80; nominal P = .034) and numerically favored TOF in AT-naive patients (64.5% vs 43.9%; OR 2.32, 95% CI 0.84-6.44). Three-year treatment persistence did not differ significantly in either cohort.
ContextThis real-world study adds to limited comparative data on TOF vs IFX in UC, particularly in AT-exposed patients, where TOF showed a significant advantage in remission rates, though findings are exploratory.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

… Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. … Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Mizuta N … Nishikawa H · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №20 Every paper GI Signals surfaces gets a page like this one. All issues